![](https://investorshub.advfn.com/uicon/163809.png?cb=1649070668)
Monday, March 31, 2014 9:12:40 PM
Should I stay in my manage care management sales position with Gilead or give these guys any consideration?
Anti seizure drug? I thought the Medical Mary Jane sector had wrapped up with Charlotte's web and Carly's Law. Alabama of all States vote on that tomorrow. The Governor has stated he will sign it into law if it makes it to his desk tomorrow. And he's a frigg'n Doctor! Compete with that.
Gilead has an arterial hypertension drug that is in an over saturated market.
Small pharma is fun to cut your teeth in on, but looking to pass.
Lower highs and lower lows. I might make a flip play on the next dip.
Recent SUPN News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 08:24:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/19/2024 08:28:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:18:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:14:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:10:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:05:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/15/2024 08:53:33 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/17/2024 09:15:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:15:31 PM
- Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 08:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:25:14 PM
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy • GlobeNewswire Inc. • 05/23/2024 08:05:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:09:06 PM
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures • GlobeNewswire Inc. • 05/09/2024 08:05:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:11:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:08:06 PM
- Supernus Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/08/2024 08:05:50 PM
- M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America • PR Newswire (US) • 05/07/2024 02:00:00 PM
- Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story • GlobeNewswire Inc. • 05/01/2024 12:00:32 PM
- Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 • GlobeNewswire Inc. • 04/24/2024 08:05:53 PM
- Supernus Provides Regulatory Update for SPN-830 • GlobeNewswire Inc. • 04/08/2024 12:00:16 PM
- Supernus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/06/2024 09:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:01:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:00:51 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM